Mayne Pharma : Wilsons investor conference presentation

Mayne Pharma

Group Limited

Wilsons Rapid Insights Conference

Company Presentation

26 May 2022

Company overview

Company Overview

• Diversified pharma with novel brands, established brands, generics and contract services
• Transformational opportunity with NEXTSTELLIS® oral contraceptive
• Dermatology go-to-market approach attracting high quality pharma partners
• Highly valued US pure play CDMO business with double digit track record of growth
• $1.5b of assets across operations
• Multiple options for near term value creation

1HFY22 reported gross profit

20%	Dermatology
	US contract services
4%	38%
International
10%	Branded inc.
	NEXTSTELLIS
28%	Retail generics

>85%	of revenue in US
80%	of gross profit in growth segments
100+	marketed products
100+	contract service clients

• internally owned manufacturing sites

15 export countries

900+ employees

1b	doses sold globally

2

US pharma market themes / challenges

Consumers		Generic Manufacturers			Brand manufacturers
• Rising costs / high out of pocket costs /		• Generic price deflation		•	Price increase backlash
coinsurance / cash		• Portfolio optimisation (shrink to grow)		•	Becoming more specialised
• Quality of insurance coverage decreasing		• Rising costs as profit shifts downstream		•	Orphan drugs
• Missed diagnosis visits due to COVID		• Supply chain integrity		•	Copay accumulators
reducing prescription utilisation		• Less concentrated market (40+ more

generic companies than 5 years ago)

	Wholesalers		Pharmacies			Payers
•	Contract negotiations		• Reimbursement		• Managing specialty drug costs
• Generic price deflation / slow brand		• Access to specialty drugs		•	Rising oncology costs
•	inflation		• Growth in alternate channels - ie. Amazon,		•	Formulary blocks
Purchasing alliances		digital pharmacies
			• Growth in cash paying customers

3

Global CDMO market is large and growing rapidly

Global CDMO market size (US$b)

Finished dosage CMO (2022)

38

30

Oral solid dose

33%

Injectable

49%

Other

18%

2022	2026
Formulation development & analytics		Contract manufacturing

4

Source: BCG

Five strategic priorities to drive shareholder value

1.	2.	3.	4.	5.
Successfully	Drive growth of	Accelerate US	International	Corporate
commercialise	dermatology in	Contract Service	growth through	initiatives to
NEXTSTELLIS® in	established and	platform investing	pipeline and	accelerate
the US	alternate channels	in broader	capacity	transformation
		capabilities and	expansion
		additional capacity

5